Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Pregnancy
Practical guidance helps safely manage blood cancer during pregnancy by weighing maternal and fetal risks thoughtfully.
This practical review synthesizes guidance for managing Philadelphia-negative MPNs during pregnancy, a high-risk clinical scenario with limited prospective evidence and competing maternal/fetal risks. The guide addresses risk stratification, medication safety, monitoring intensity, and obstetric planning for hematologists and obstetricians co-managing this rare but clinically challenging condition.
What the study was
- Study design
- Narrative review
- Population
- Pregnant women with Philadelphia-negative MPNs (polycythemia vera, essential thrombocythemia, primary myelofibrosis)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Oncology
Why it surfaced
Management guide for MPNs in pregnancy—an underserved clinical scenario with limited evidence—useful for hematologists and obstetricians managing this high-risk population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.